WO2000049019A3 - Novel epothilone derivatives, method for producing them and their pharmaceutical use - Google Patents
Novel epothilone derivatives, method for producing them and their pharmaceutical use Download PDFInfo
- Publication number
- WO2000049019A3 WO2000049019A3 PCT/EP2000/001331 EP0001331W WO0049019A3 WO 2000049019 A3 WO2000049019 A3 WO 2000049019A3 EP 0001331 W EP0001331 W EP 0001331W WO 0049019 A3 WO0049019 A3 WO 0049019A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- novel
- epothilone derivatives
- tumours
- order
- Prior art date
Links
- 150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102000004243 Tubulin Human genes 0.000 abstract 1
- 108090000704 Tubulin Proteins 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000003527 anti-angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 abstract 1
- 210000003128 head Anatomy 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 210000003739 neck Anatomy 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000002861 polymer material Substances 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38048/00A AU3804800A (en) | 1999-02-18 | 2000-02-18 | Novel epothilone derivatives, method for producing them and their pharmaceuticaluse |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19908760.1 | 1999-02-18 | ||
DE19908760A DE19908760A1 (en) | 1999-02-18 | 1999-02-18 | New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000049019A2 WO2000049019A2 (en) | 2000-08-24 |
WO2000049019A3 true WO2000049019A3 (en) | 2001-03-01 |
Family
ID=7899229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/001331 WO2000049019A2 (en) | 1999-02-18 | 2000-02-18 | Novel epothilone derivatives, method for producing them and their pharmaceutical use |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3804800A (en) |
DE (1) | DE19908760A1 (en) |
WO (1) | WO2000049019A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41990E1 (en) | 1996-12-03 | 2010-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL207197B1 (en) * | 2001-02-27 | 2010-11-30 | Novartis Ag | Combination comprising a signal transduction inhibitor and an epothilone derivative |
JP2004529904A (en) * | 2001-03-14 | 2004-09-30 | ブリストル−マイヤーズ スクイブ カンパニー | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
AU2008203233B2 (en) * | 2001-07-19 | 2010-04-29 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20030176368A1 (en) * | 2001-09-06 | 2003-09-18 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
ES2337134T3 (en) | 2002-03-12 | 2010-04-21 | Bristol-Myers Squibb Company | DERIVATIVES OF C3-CIANO-EPOTILONE. |
MXPA04012444A (en) * | 2002-06-10 | 2005-04-19 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof. |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
SI1767535T1 (en) | 2002-08-23 | 2010-03-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
EP1959952A4 (en) * | 2005-11-22 | 2011-02-23 | Scripps Research Inst | Chemical synthesis of a highly potent epothilone |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (en) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Enzymatic binding of polypeptides |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019086A1 (en) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
WO1999007692A2 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
WO1999065913A2 (en) * | 1998-06-18 | 1999-12-23 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone minor constituents |
-
1999
- 1999-02-18 DE DE19908760A patent/DE19908760A1/en not_active Withdrawn
-
2000
- 2000-02-18 WO PCT/EP2000/001331 patent/WO2000049019A2/en active Search and Examination
- 2000-02-18 AU AU38048/00A patent/AU3804800A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019086A1 (en) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
WO1999007692A2 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
WO1999065913A2 (en) * | 1998-06-18 | 1999-12-23 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone minor constituents |
Non-Patent Citations (7)
Title |
---|
CHOU T C ET AL: "DESOXYEPOTHILONE B: AN EFFICACIOUS MICROTUBULE-TARGETED ANTITUMOR AGENT WITH A PROMISING IN VIVO PROFILE RELATIVE TO EPOTHILONE B", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 95, no. 16, 1998, pages 9642 - 9647, XP000910107, ISSN: 0027-8424 * |
D SCHINZER ET AL: "ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM", ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM, vol. 109, no. 5, 1997, pages 543 - 544, XP002095720, ISSN: 0044-8249 * |
HANESSIAN, STEPHEN ET AL: "Total Synthesis and Absolute Configuration of (-)-Anthoplalone", J. ORG. CHEM. (1999), 64(13), 4893-4900, XP002152894 * |
K C NICOLAOU ET AL: "ANGEWANDTE CHEMIE,VCH VERLAGSGESELLSCHAFT, WEINHEIM,DE", ANGEWANDTE CHEMIE,VCH VERLAGSGESELLSCHAFT, WEINHEIM,DE, vol. 109, no. 19, 1997, pages 2181 - 2187, XP002095723, ISSN: 0044-8249 * |
K C NICOLAOU ET AL: "NATURE,MACMILLAN JOURNALS LTD. LONDON,GB", NATURE,MACMILLAN JOURNALS LTD. LONDON,GB, vol. 387, no. 6630, 15 May 1997 (1997-05-15), pages 268 - 272, XP002095721, ISSN: 0028-0836 * |
K C NICOLAOU ET AL: "Probing the ring size of epothilones: total synthesis of [14]-, [15]-, [17]-, and [18]Epothilones A", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION,DE,VERLAG CHEMIE. WEINHEIM, vol. 37, no. 1/02, 1998, pages 81 - 84, XP002131226, ISSN: 0570-0833 * |
ZHEN YANG ET AL: "ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM", ANGEWANDTE CHEMIE,DE,VCH VERLAGSGESELLSCHAFT, WEINHEIM, vol. 109, no. 1/02, 1997, pages 170 - 172, XP002095722, ISSN: 0044-8249 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41990E1 (en) | 1996-12-03 | 2010-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2000049019A2 (en) | 2000-08-24 |
AU3804800A (en) | 2000-09-04 |
DE19908760A1 (en) | 2000-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000049019A3 (en) | Novel epothilone derivatives, method for producing them and their pharmaceutical use | |
WO1999007692A3 (en) | New epothilone derivatives, method for producing same and their pharmaceutical use | |
TW200711679A (en) | Combination of epothilone derivatives | |
WO2000049020A3 (en) | Novel epothilon derivatives, method for the production thereof and their pharmaceutical application | |
WO2001081342A3 (en) | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use | |
GEP20022653B (en) | Processes and Intermediates for Preparing Anti-Cancer Compounds | |
EG24928A (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
TW200635948A (en) | Tripeptide and tetrapeptide thioethers | |
ATE171171T1 (en) | ALPHA-AMINOKETONE DERIVATIVES | |
TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
GEP20043250B (en) | Use of Indolyl-3-Glyoxylic Acid Derivatives as Anti-tumor Means and Pharmaceutical Compositions Containing the Same | |
DE69907419D1 (en) | Antitumorwirkstoffe | |
DE60209721D1 (en) | OXAZOLO AND FUROPYRIMIDINES AND THEIR USE AS MEDICAMENTS AGAINST TUMORS | |
CA2081343A1 (en) | Therapeutic agents for the treatment of multidrug resistance to cancers | |
MY133474A (en) | Aryl fused azapolycyclic compounds | |
WO2001081341A3 (en) | 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations | |
AU672644B2 (en) | Aryl substituted heterocyclic compounds | |
ATE340573T1 (en) | USE OF 7-NITRO-2,1,3-BENZOXADIAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | |
WO2001046178A3 (en) | Substituierte bisindolymaleimide | |
ATE186214T1 (en) | USE OF ROSMANOL DERIVATIVES FOR THE PRODUCTION OF ANTIRADICAL AND/OR ANTILIPOPEROXIDATIVE AND/OR HEPATOTROPIC DRUGS | |
YU43302A (en) | Substituted bisindolylmaleimides for the inhibition of cell proliferation | |
DE69132050D1 (en) | COMPOSITIONS OF GROWTH FACTORS, PRODUCTION AND USE | |
ATE444755T1 (en) | USE OF TOPOTECAN IN THE PRODUCTION OF A MEDICATION FOR USE IN THE TREATMENT OF OVARIAL CANCER | |
ES2200706A1 (en) | Derivatives of 4-4'-bipyridyl-2-2'-bisoxazoles and 4-4'-bipyridyl-2-2'-bistiazoles as antineoplasic agents | |
HK1082727A1 (en) | 2" oxo-voruscharin and derivatives thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |